Infectious Disease Point-of-care (POC) Diagnostics Market

Global Infectious Disease Point-of-care (POC) Diagnostics Market Report: By Technique (Lateral Flow Immunoassay (LFIA), Agglutination Test, Flow-through test/Immunoconcentration Assay, Molecular Diagnostics, and Others) By Disease (HIV, Hepatitis B Virus, Pneumonia/Streptococcus Associated Infections, Respiratory Syncytial Virus (RSV), Influenza, Clostridium Difficile Infections (CDI), Hepatitis C Virus, Methicillin-Resistant Staphylococcus Aureus (MRSA), Tuberculosis (TB), COVID-19, Others) and Region (North America, Europe, Asia-Pacific, Latin America, Middle-East and Africa) Global Industry Analysis, Size, Share, Growth, Trends, Regional Analysis, Competitor Analysis and Forecast 2023-2031.

Medical Devices | January 2024 | Report ID: EMR00417 | Pages: 301

Global Infectious Disease Point-of-care (POC) Diagnostics market is predicted to reach approximately USD 12.35 billion by 2031, at a CAGR of -1.65% from 2022 to 2031.

The global infectious disease Point-of-care (POC) Diagnostics market is witnessing significant growth driven by advancements in diagnostic technologies and increasing demand for rapid and accurate disease detection. Point-of-care diagnostics refer to medical testing conducted near or at the site of patient care, providing immediate results for informed decision-making. These diagnostics play a crucial role in infectious disease management, enabling timely interventions and reducing the spread of infections. The market encompasses a diverse range of diagnostic techniques, including Lateral Flow Immunoassay (LFIA), Agglutination Test, Flow-through test/Immunoconcentration Assay, and Molecular Diagnostics. Diseases covered in this market include HIV, Hepatitis B and C, Pneumonia/Streptococcus Associated Infections, Respiratory Syncytial Virus (RSV), Influenza, Clostridium Difficile Infections (CDI), Methicillin-Resistant Staphylococcus Aureus (MRSA), Tuberculosis (TB), and the pivotal focus on COVID-19.



Global Infectious Disease Point-of-care (POC) Diagnostics report scope and segmentation.

Report Attribute


Estimated Market Value (2022)

USD 14.35 billion

Projected Market Value (2031)

USD 12.35 billion

Base Year


Forecast Years

2023 – 2031

Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Based on By Technique, Disease, End-User & Region.

Segments Covered

By Technique, Disease, End-User & By Region.

Forecast Units

Value (USD Billion or Million), and Volume (Units)

Quantitative Units

Revenue in USD million/billion and CAGR from 2023 to 2031.

Regions Covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Countries Covered

U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others.

Report Coverage

Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis.

Delivery Format

Delivered as an attached PDF and Excel through email, according to the purchase option.


Global Infectious Disease Point-of-care (POC) Diagnostics dynamics

The dynamic factors that are reshaping the healthcare diagnostics landscape are driving the diagnostics market. The market is expanding due to the quick developments in diagnostic technologies, especially in the areas of molecular diagnostics and immunoassays. The creation and marketing of cutting-edge point-of-care diagnostic instruments is a result of the growing need for prompt and precise diagnostic solutions, particularly in the context of infectious diseases. These developments enable medical personnel to make prompt, well-informed decisions that ultimately improve patient outcomes and stop the spread of infectious diseases.

The market is witnessing a surge in demand due to the global prevalence of infectious diseases, with a particular spotlight on the ongoing COVID-19 pandemic. The need for decentralized healthcare solutions is fuelling the adoption of point-of-care diagnostics across diverse settings, ranging from hospitals and clinics to retail clinics and even home-based testing. Additionally, the market is characterized by collaborations, partnerships, and strategic initiatives among key players to enhance product portfolios, expand market reach, and accelerate technological advancements.


Global Infectious Disease Point-of-care (POC) Diagnostics drivers

  • Advancements in Diagnostic Technologies  

The global infectious disease Point-of-care (POC) Diagnostics market is significantly driven by ongoing advancements in diagnostic technologies, particularly in molecular diagnostics and immunoassays. Early intervention and better patient outcomes are promoted by the quicker and more accurate detection of infectious agents made possible by the development of more sensitive and focused diagnostic instruments. Technological developments also add to the diversity of diagnostic techniques by providing a wide range of point-of-care solutions that efficiently address different infectious diseases.

  • Increasing Global Prevalence of Infectious Diseases  

The rising prevalence of infectious diseases worldwide, including the ongoing challenges posed by pandemics such as COVID-19, serves as a key driver for the market. The growing incidence of diseases like HIV, hepatitis, influenza, and antibiotic-resistant infections underscores the need for rapid and decentralized diagnostic solutions. Point-of-care diagnostics play a pivotal role in containing the spread of infectious agents by facilitating timely diagnosis, enabling prompt treatment, and minimizing the risk of transmission within communities.



  • Regulatory Challenges and Stringent Approvals

The market for point-of-care diagnostics for infectious diseases faces difficulties with regulatory approvals and compliance. Strict legal requirements and lengthy approval procedures can make it take a lot longer for new diagnostic technologies to reach the market. Managing intricate regulatory environments is a hindrance that slows down the rate at which patients and healthcare providers can access cutting-edge diagnostic solutions.

  • Limited Reimbursement Policies

Restricted reimbursement policies for point-of-care diagnostic tests are impeding the market. The widespread use of these diagnostics may be hampered by reimbursement issues, especially in healthcare systems where financial concerns are very important. The lack of comprehensive reimbursement may have an effect on point-of-care test affordability and accessibility, which may restrict the tests' ability to be integrated into standard clinical practice.



  • Expansion of Point-of-Care Testing in Emerging Markets  

The expansion of point-of-care testing in emerging markets presents a significant opportunity for market growth. Point-of-care diagnostics adoption is encouraged by rising public awareness of infectious diseases and initiatives to improve healthcare facilities in developing nations. The implementation of strategic market penetration and partnerships in developing nations has the potential to enhance the availability and adoption of these diagnostic tools.


Segment Overview

  • By Technique

The technique segment encompasses various diagnostic methodologies, each designed to cater to specific infectious disease testing requirements. Lateral Flow Immunoassay (LFIA) stands out as a rapid and user-friendly method, allowing for quick on-site detection. Agglutination tests utilize the clumping of particles for identification, while Flow-through tests or Immunoconcentration Assays enhance sensitivity through targeted concentration techniques. Molecular Diagnostics, involving the analysis of nucleic acids, provides a high level of precision in identifying infectious agents. The inclusion of 'Others' reflects the continual evolution and diversification of diagnostic techniques within the infectious disease POC diagnostics market.

  • By Disease

Disease segmentation highlights the versatility of POC diagnostics in addressing a broad spectrum of infectious conditions. HIV, Hepatitis B and C viruses, respiratory infections like pneumonia and those associated with Streptococcus and Respiratory Syncytial Virus (RSV), as well as influenza, underscore the market's commitment to combating viral infections. Clostridium Difficile Infections (CDI) and Methicillin-Resistant Staphylococcus Aureus (MRSA) showcase a focus on bacterial infections, while Tuberculosis (TB) remains a significant target for POC diagnostics. The inclusion of COVID-19 emphasizes the market's adaptability to emerging infectious threats, and the others category acknowledges the ongoing challenge of diverse infectious diseases worldwide.

  • By End-User

End-users represent the diverse settings where POC diagnostics are deployed. Hospitals leverage these technologies for efficient and timely patient care, bedside applications ensure immediate results for critical cases, and physician's offices benefit from the accessibility of point-of-care testing. Laboratories maintain a central role in comprehensive diagnostics, while urgent care and retail clinics serve as accessible community-based hubs. Home and self-testing options empower individuals in monitoring their health, especially in chronic conditions. Nursing homes cater to the unique diagnostic needs of elderly populations. The inclusion of 'Others' acknowledges the adaptability of POC diagnostics to various healthcare settings, promoting accessibility and timely interventions across the healthcare continuum.


Global Infectious Disease Point-of-care (POC) Diagnostics Overview by Region

The global infectious disease Point-of-care (POC) Diagnostics market exhibits a diverse regional landscape with varying healthcare infrastructures, prevalence of infectious diseases, and regulatory environments. North America, as a mature market, holds a significant share, driven by robust healthcare systems, high awareness, and early adoption of advanced diagnostic technologies. The region benefits from the presence of key market players and substantial investments in research and development.

Preventive medicine and decentralised healthcare delivery are becoming more and more important in the European market. Growth in the point-of-care diagnostics market is facilitated by the government's increasing efforts to combat infectious diseases. Due to growing healthcare infrastructure, a rise in infectious disease prevalence, and general population awareness, the Asia-Pacific region is becoming a lucrative market. Because of their expansive and varied healthcare systems, major economies like China and India are seeing a rise in the demand for point-of-care diagnostics.

Latin America and the Middle East & Africa exhibit untapped potential, with increasing investments in healthcare infrastructure and a growing need for rapid and accessible diagnostic solutions. These regions, while facing unique challenges such as economic constraints and healthcare disparities, present opportunities for market players to address unmet diagnostic need.



Global Infectious Disease Point-of-care (POC) Diagnostics market competitive landscape

The competitive landscape of the global infectious disease Point-of-care (POC) Diagnostics market is characterized by intense competition among key players striving for market dominance through innovation, strategic collaborations, and geographic expansion. F. Hoffmann-La Roche Ltd from Switzerland stands out as a prominent player, leveraging its strong portfolio of diagnostic solutions, including molecular diagnostics and immunoassays. Thermo Fisher Scientific Inc. (U.S.) and Abbott Laboratories (U.S.) are formidable contenders, recognized for their cutting-edge technologies and global market presence.

Quest Diagnostics Incorporated (U.S.) and BD (U.S.) are key players contributing to the competitive dynamics, with a focus on expanding their product portfolios and catering to a wide range of infectious diseases. bioMérieux SA (France) is at the forefront of driving innovation in diagnostic solutions, particularly in the field of microbiology. Cardinal Health, Inc. (U.S.) and Cepheid (U.S.) play pivotal roles, offering a diverse range of point-of-care diagnostic solutions and collaborating with healthcare providers to enhance patient outcomes.

Trinity Biotech (Ireland), Quidel Corporation (U.S.), and Bio-Rad Laboratories Inc. (U.S.) also contribute significantly to the competitive landscape, leveraging their expertise in developing rapid diagnostic tests and molecular diagnostic platforms. These companies engage in strategic partnerships and acquisitions to strengthen their market position and expand their global footprint.


Global Infectious Disease Point-of-care (POC) Diagnostics Recent Developments

  • Jan 2023, Cipla is broadening its diagnostics portfolio with the introduction of a new point-of-care testing device called Cippoint. This latest addition to Cipla's diagnostic laboratory products provides an extensive array of testing parameters, encompassing cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers.
  • May 2023, Sensible Diagnostics, a start-ups based in Los Angeles, claims to have created a compact and affordable instrument capable of conducting PCR in just 10 minutes. The company plans to introduce its system, along with inexpensive test cartridges, in early 2024, with an initial focus on point-of-care infectious disease testing.


Scope of global Infectious Disease Point-of-care (POC) Diagnostics report

Global Infectious Disease Point-of-care (POC) Diagnostics report segmentation



By Technique

  • Lateral Flow Immunoassay (LFIA)
  • Agglutination Test
  • Flow-through test/Immunoconcentration Assay
  • Molecular Diagnostics
  • Others

By Disease

  • HIV
  • Hepatitis B Virus
  • Pneumonia/Streptococcus Associated Infections
  • Respiratory Syncytial Virus (RSV)
  • Influenza
  • Clostridium Difficile Infections (CDI)
  • Hepatitis C Virus
  • Methicillin-Resistant Staphylococcus Aureus (MRSA)
  • Tuberculosis (TB)
  • COVID-19
  • Others

By End-User

  • Hospital
  • Bedside
  • Physician's Office
  • Lab
  • Urgent Care & Retail Clinics
  • Home & Self-testing
  • Nursing Home
  • Others

By Geography

  • North America (USA, and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Russia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Customization Scope

  • Available upon request


  • Available upon request


Objectives of the Study

The objectives of the study are summarized in 5 stages. They are as mentioned below:

  • Global Infectious Disease Point-of-care (POC) Diagnostics size and forecast: To identify and estimate the market size for global Infectious Disease Point-of-care (POC) Diagnostics market segmented by Technique, Disease, End-User and by region. Also, to understand the consumption/ demand created by consumers between 2023 and 2031.
  • Market Landscape and Trends: To identify and infer the drivers, restraints, opportunities, and challenges for global Infectious Disease Point-of-care (POC) Diagnostics
  • Market Influencing Factors: To find out the factors which are affecting the market of global Infectious Disease Point-of-care (POC) Diagnostics among consumers.
  • Company Profiling:  To provide a detailed insight into the major companies operating in the market. The profiling will include the financial health of the company's past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.

Research Methodology

Our research methodology has always been the key differentiating reason which sets us apart in comparison from the competing organizations in the industry. Our organization believes in consistency along with quality and establishing a new level with every new report we generate; our methods are acclaimed and the data/information inside the report is coveted. Our research methodology involves a combination of primary and secondary research methods. Data procurement is one of the most extensive stages in our research process. Our organization helps in assisting the clients to find the opportunities by examining the market across the globe coupled with providing economic statistics for each and every region.  The reports generated and published are based on primary & secondary research. In secondary research, we gather data for global Market through white papers, case studies, blogs, reference customers, news, articles, press releases, white papers, and research studies. We also have our paid data applications which includes hoovers, Bloomberg business week, Avention, and others.

Data Collection

Data collection is the process of gathering, measuring, and analyzing accurate and relevant data from a variety of sources to analyze market and forecast trends. Raw market data is obtained on a broad front. Data is continuously extracted and filtered to ensure only validated and authenticated sources are considered. Data is mined from a varied host of sources including secondary and primary sources.

Primary Research

After the secondary research process, we initiate the primary research phase in which we interact with companies operating within the market space. We interact with related industries to understand the factors that can drive or hamper a market. Exhaustive primary interviews are conducted. Various sources from both the supply and demand sides are interviewed to obtain qualitative and quantitative information for a report which includes suppliers, product providers, domain experts, CEOs, vice presidents, marketing & sales directors, Type & innovation directors, and related key executives from various key companies to ensure a holistic and unbiased picture of the market. 

Secondary Research

A secondary research process is conducted to identify and collect information useful for the extensive, technical, market-oriented, and comprehensive study of the market. Secondary sources include published market studies, competitive information, white papers, analyst reports, government agencies, industry and trade associations, media sources, chambers of commerce, newsletters, trade publications, magazines, Bloomberg BusinessWeek, Factiva, D&B, annual reports, company house documents, investor presentations, articles, journals, blogs, and SEC filings of companies, newspapers, and so on. We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

Top-Down Approach & Bottom-Up Approach

In the top – down approach, the Global Batteries for Solar Energy Storage Market was further divided into various segments on the basis of the percentage share of each segment. This approach helped in arriving at the market size of each segment globally. The segments market size was further broken down in the regional market size of each segment and sub-segments. The sub-segments were further broken down to country level market. The market size arrived using this approach was then crosschecked with the market size arrived by using bottom-up approach.

In the bottom-up approach, we arrived at the country market size by identifying the revenues and market shares of the key market players. The country market sizes then were added up to arrive at regional market size of the decorated apparel, which eventually added up to arrive at global market size.

This is one of the most reliable methods as the information is directly obtained from the key players in the market and is based on the primary interviews from the key opinion leaders associated with the firms considered in the research. Furthermore, the data obtained from the company sources and the primary respondents was validated through secondary sources including government publications and Bloomberg.

Market Analysis & size Estimation

Post the data mining stage, we gather our findings and analyze them, filtering out relevant insights. These are evaluated across research teams and industry experts. All this data is collected and evaluated by our analysts. The key players in the industry or markets are identified through extensive primary and secondary research. All percentage share splits, and breakdowns have been determined using secondary sources and verified through primary sources. The market size, in terms of value and volume, is determined through primary and secondary research processes, and forecasting models including the time series model, econometric model, judgmental forecasting model, the Delphi method, among Flywheel Energy Storage. Gathered information for market analysis, competitive landscape, growth trends, product development, and pricing trends is fed into the model and analyzed simultaneously.

Quality Checking & Final Review

The analysis done by the research team is further reviewed to check for the accuracy of the data provided to ensure the clients’ requirements. This approach provides essential checks and balances which facilitate the production of quality data. This Type of revision was done in two phases for the authenticity of the data and negligible errors in the report. After quality checking, the report is reviewed to look after the presentation, Type and to recheck if all the requirements of the clients were addressed.

Frequently Asked Questions

Global Infectious Disease Point-of-care (POC) Diagnostics forecast period is 2023 - 2031.
According to global Infectious Disease Point-of-care (POC) Diagnostics research, the market is expected to grow at a CAGR of ~-1.65% over the next eight years.
The possible segments in global Infectious Disease Point-of-care (POC) Diagnostics are based on by Technique, Disease, End-User & by region.
The expected market size for Global Infectious Disease Point-of-care (POC) Diagnostics is USD 14.35 billion in 2022.
The major players in the market are Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Quest Diagnostics Incorporated (U.S.), BD (U.S.), bioMerieux SA (France), Cardinal Health, Inc. (U.S.), Cepheid (U.S.), Trinity Biotech (Ireland), Quidel Corporation (U.S.), Bio-Rad Laboratories Inc. (U.S.) and F. Hoffmann-La Roche Ltd (Switzerland).